Skip to main content
Equibles
BCRX logo

BCRX · Biocryst Pharmaceuticals Inc · Metrics

Track BCRX — free

Use BCRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.98 -0.09 (-0.94%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.33B
Shares
255.54M

BCRX metrics

76 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.07
Market cap
$2.33B

Price action

20 metrics
Price change (1W)
+1.4%
Price change (30D)
+1.2%
Price change (3M)
+18.4%
Price change (6M)
+17.5%
Price change (YTD)
+27.7%
Price change (1Y)
+20.4%
Trailing year
Price change (5Y)
-36.4%
52-week high
$11.11
52-week low
$6.24
Change from 52-week high
-10.4%
Change from 52-week low
+59.6%
Annualized volatility
47.4%
Annualized volatility (3M)
46.7%
Beta
0.6
RSI (14D)
53.5
Price vs SMA 50
+2.2%
Price vs SMA 200
+16.2%
Avg volume (3M)
4.22M
Relative volume
0.4
Average dollar volume
$40.69M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
255.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.5×
reciprocal yield 39.6%
EV / EBITDA
6.0×
reciprocal yield 16.6%
EV / EBIT
—
P / sales
2.5×
reciprocal yield 40.3%
P / book
—
FCF yield
16.0%
TTM · current market cap
Buyback yield
0.0%
P / FCF
6.3
reciprocal yield 16.0%
P / operating cash flow
6.2
reciprocal yield 16.1%
Earnings yield
-16.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
28.1×
reciprocal yield 3.6%
EV / revenue historical average (5Y)
28.1×
reciprocal yield 3.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
97.8%
Operating margin
-33.3%
Trailing 12 months
Net margin
-40.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$313.16M
Net income (TTM)
−$384.67M
Trailing 12 months
Diluted EPS (TTM)
$-1.49
FCF margin
39.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.46

Growth

11 metrics
Revenue growth YoY
+33.6%
Year over year
Net income growth YoY
+1,441.7%
Revenue (TTM)
$940.61M
Trailing 12 months
EPS growth YoY
+1,400.0%
Shares change YoY
+20.6%
Year over year · more shares
Revenue CAGR (3Y)
+47.8%
Revenue CAGR (5Y)
+117.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-69.0%
Debt / equity
—
Current ratio
2.3
EBITDA (TTM)
$342.38M
Free cash flow (TTM)
$373.38M
Quick ratio
2.3
Interest coverage
-4.2
Net debt / EBITDA
-0.8
Return on invested capital
—
Trailing 12 months
Net cash
−$42.83M
Latest balance sheet
Cash & equivalents
$154.97M
Total assets
$557.85M
Total debt
$395.40M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$376.13M
Capital expenditures (TTM)
$2.76M
R&D (TTM)
$197.76M
SG&A (TTM)
$337.32M
Stock compensation (TTM)
$73.11M
R&D / revenue
21.0%
Stock compensation / revenue
7.8%

Ownership (13F)

3 metrics
13F filers
320
13F filer change QoQ
+16
Institutional ownership
103.3%

Short interest

3 metrics
Short interest
12.9%
Latest settlement · 8.0 days to cover
Days to cover
8.0d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 882796 CUSIP 09058V103 13F (30d) 208 filings 206 filers Visit website Investor relations